Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SPM 5185

Drug Profile

SPM 5185

Latest Information Update: 20 May 1996

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schwarz Pharma
  • Developer Thomas Jefferson University
  • Class Anti-ischaemics; Antiplatelets; Heart failure therapies; Organic nitrates; Vasodilators
  • Mechanism of Action Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Myocardial ischaemia

Most Recent Events

  • 20 May 1996 An in vitro study has been added to the pharmacodynamics section for Ischaemic Heart Disease .
  • 29 Mar 1996 Discontinued-Preclinical for Heart failure in USA (Unknown route)
  • 29 Mar 1996 Discontinued-Preclinical for Myocardial ischaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top